Journal: Journal of Translational Medicine

Article Title: Dynamic remodelling of epithelial plasticity in colorectal cancer from single-cell and spatially resolved perspectives

doi: 10.1186/s12967-025-07380-8

Figure Lengend Snippet: SCAND1 promotes colorectal cancer cell proliferation, anti-apoptotic, migration, invasion, and EMT. ( A ) SCAND1 protein expression in normal and various colorectal cancer cell lines. ( B - C ) Protein ( B ) and mRNA ( C ) expression levels of SCAND1 were detected by western blotting and RT-qPCR. ( D ) EDU assay analysis. ( E ) Apoptosis rate was detected by flow cytometry. ( F - G ) Wound healing, migration and invasion assay analysis. ( H ) Western blotting was used to detect the expression levels of ZEB2, E-cadherin, N-cadherin, vimentin, α-SMA, and Twist1 in HCT116 and SW620 cells. ( I - J ) Apoptosis and growth assessment of HCT116 after co-culture with Jurkat cells. EMT: Epithelial–mesenchymal transition. * p < 0.05; ** p < 0.01; *** p < 0.001, compared to the corresponding groups

Article Snippet: The primary antibodies are used as follows: SCAND1 (1:1,000; Thermofisher, PA5-49816), β-actin (1:4,000; ProteinTech, 66009–1-Ig), ZEB2(1:1,000; ProteinTech, 14026–1-AP), Twist1(1:1,000; ProteinTech, 25465–1-AP), N-Cadherin(1:1,000; ProteinTech, 22018–1-AP), E-Cadherin(1:1,000; ProteinTech, 20874–1-AP), α-SMA(1:1,000; ProteinTech, 14395–1-AP), Vimentin(1:1,000; ProteinTech, 10366–1-AP), β-tubulin (1:4,000; ProteinTech, 10094–1-AP).

Techniques: Migration, Expressing, Western Blot, Quantitative RT-PCR, EdU Assay, Flow Cytometry, Invasion Assay, Co-Culture Assay

Journal: Non-coding RNA research

Article Title: Upregulation of LINC02154 promotes esophageal cancer progression by enhancing cell cycling and epithelial-mesenchymal transition.

doi: 10.1016/j.ncrna.2025.06.001

Figure Lengend Snippet: Fig. 4. LINC02154 promotes EMT through suppression of miR-200b. (A) Correlation between levels of miR-200b expression and those of LINC02154 expression in TCGA-ESCA dataset. (B) Putative miR-200b-3p binding sites in the LINC02154 sequence. (C) qRT-PCR analysis of miR-200b in TE-5 cells transfected with a control siRNA or siRNAs targeting LINC02154. (n = 3). (D) Western blot analysis of ZEB2 in TE-5 cells transfected with the indicated siRNAs. (E) Correlation between levels of miR-200b expression and those of VIM in TCGA-ESCA dataset. (F) Correlation between VIM expression and T-factors (left) and clinical stages (right) in TCGA-ESCA dataset. (G) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-mimic control or a miR-200b mimic. (n = 3). (H) qRT-PCR analysis of VIM in ESCA cells transfected with a miR-inhibitor control or a miR-200b inhibitor. (n = 3). (I, J) Results of cell viability assays in ESCA cells infected with the indicated vectors. Cells were treated with the indicated concentrations of cisplatin (H) or 5-FU (I). (n = 6). Error bars represent SDs. **P < 0.01, ***P < 0.001, NS, not significant.

Article Snippet: A mouse monoclonal anti-GAPDH mAb (1:5000 dilution, HRP-60004, Proteintech, Rosemont, IL, USA), rabbit monoclonal anti-cyclin B1 mAb (1:1000 dilution, #12231, Cell Signaling Technology, Danvers, MA, USA), and rabbit recombinant anti-ZEB2 antibody (1:3000 dilution, 82020-1-RR, Proteintech) were used.

Techniques: Expressing, Binding Assay, Sequencing, Quantitative RT-PCR, Transfection, Control, Western Blot, Infection